$CLOV

Soares Karen sold $22K of CLOV

Soares Karen (Chief Legal Officer) sold 4,681 shares of CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) at $4.61 on 2026-06-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Soares Karen
Published Jun 16, 2026, 12:16 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 16, 2026, 12:37 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CLOV
Neutral
high confidence
Mentioned
$CLOV
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CLOVNeutralLow
01

Why it matters

The newest fact is the officer’s open-market sale amount, price, and post-transaction holdings, disclosed as part of a pre-arranged 10b5-1 plan.

02

Market read

Traders may monitor insider activity for sentiment, but this specific disclosure is unlikely to drive a major repricing without additional fundamental catalysts.

03

What to watch

The article provides only the sale details; it does not indicate whether there were concurrent buys, option exercises, or broader insider activity trends.

Relevance 2/10Novelty 6/10Timing: Filed 2026-06-16; transaction dated 2026-06-15

Background

The article is an SEC Form 4 insider transaction disclosure for Clover Health Investments, Corp./DE.

Company-level read

Ticker impact

$CLOVNeutralHigh confidence
Context

Clover Health’s Chief Legal Officer Karen Soares sold 4,681 shares in an open-market transaction under a pre-arranged 10b5-1 plan.

Expected impact

Likely limited near-term impact; any effect should be small and short-lived unless paired with other news.

Evidence & confidence

The filing is a standard officer sale with a stated 10b5-1 plan, providing disclosure but no new operating/regulatory/financial information.

Market effects

Minimal; this is company-specific insider transaction disclosure, not a sector-wide signal.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can still be interpreted by some traders as confidence erosion, especially if it clusters with other negative signals.

Key entities

  • Clover Health Investments, Corp./DE

    Subject of the Form 4 insider transaction disclosure.

  • Karen Soares

    Chief Legal Officer who sold shares under a pre-arranged 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ASTHMed

Astrana Health, Clover Health, Alignment Healthcare, and Novavax Stocks Trade Down, What You Need To Know

Several healthcare stocks fell after bipartisan lawmakers introduced the Protecting Approved Care Act, which aims to reform Medicare Advantage plans. The bill could increase medical loss ratios and administrative burdens for insurers. Astrana Health (ASTH) fell 2.7%, Clover Health (CLOV) 4.8%, Alignment Healthcare (ALHC) 12.6%, and Novavax (NVAX) 3.6%.

$CLOVHigh

Clover Health (CLOV) Gets New ‘Buy’ Call, Higher PT, Climbs 8.5%

Clover Health (CLOV) shares rose 8.53% to $4.71 after Deutsche Bank initiated coverage with a 'buy' rating and $6 price target, citing growth potential in Medicare Advantage and its technology platform. The company reported Q2 net income of $28M, up from a $10.6M loss YoY, with revenues increasing 55.6% to $743.2M. Medicare Advantage membership grew 48% to 157,309. Clover raised its net income and revenue guidance for the year. Hedge fund holdings in CLOV increased fourfold to $79.06M.

$CLOVMed

Clover Health (CLOV) Shares Skyrocket, What You Need To Know

Clover Health (CLOV) shares rose 8.5% after Deutsche Bank initiated coverage with a Buy rating and $6.00 price target, citing growth in Medicare Advantage, its Clover Assistant platform, and its risk model. The stock has seen high volatility, with a 24.2% drop last year due to disappointing earnings and lowered guidance. CLOV is up 96.9% YTD but trades 12.3% below its 52-week high.

$PGNYHighAI 8/10

Spotting Winners: Progyny (NASDAQ:PGNY) And Health Insurance Providers Stocks In Q2

Progyny (PGNY) and other health insurers reported Q2 earnings, with revenues beating estimates by 2.8% but guidance below expectations. PGNY's revenue grew 5.3% YoY, missing EBITDA guidance. CVS Health (CVS) reported 7.3% YoY revenue growth, beating estimates. Molina Healthcare (MOH) saw a 4.8% YoY revenue decline. Alignment Healthcare (ALHC) grew 31.6% YoY, while Clover Health (CLOV) saw 55.6% YoY growth. Stocks have declined since earnings, except CLOV, which rose 4.3%.

$CLOVHighAI 8/10

Clover Health (CLOV) Turns Profitable As Medicare Membership Explodes

Clover Health (CLOV) reported Q2 2026 net income of $28M, reversing a $10.6M loss from the prior year. Medicare Advantage membership grew 48% YoY to 157,309. Revenue rose 55.6% to $743.2M, and adjusted EBITDA more than doubled. The company raised its full-year guidance, including adjusted EBITDA to $70M-$85M and GAAP net income to $20M-$35M. Cash and investments increased 13.8% YoY to $443.0M.